Dyne Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DYN research report →
Companywww.dyne-tx.com
Dyne Therapeutics, Inc. , a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
- CEO
- John G. Cox
- IPO
- 2020
- Employees
- 192
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $2.90B
- P/E
- -6.42
- P/S
- 0.00
- P/B
- 3.35
- EV/EBITDA
- -4.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.28%
- ROIC
- -45.57%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-446,214,000 · -40.58%
- EPS
- $-3.47 · -2.97%
- Op Income
- $-468,184,000
- FCF YoY
- -37.45%
Performance & Tape
- 52W High
- $25.00
- 52W Low
- $8.06
- 50D MA
- $18.36
- 200D MA
- $17.05
- Beta
- 1.08
- Avg Volume
- 2.02M
Get TickerSpark's AI analysis on DYN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Friedl-Naderer Johanna | sell | 228 |
| May 13, 26 | Kerr Douglas | sell | 1,564 |
| May 13, 26 | Lucera Erick | sell | 1,448 |
| May 13, 26 | Cox John | sell | 3,311 |
| May 4, 26 | Rhodes Jason P | sell | 6,241 |
| May 5, 26 | Rhodes Jason P | sell | 6,081 |
| May 6, 26 | Rhodes Jason P | sell | 43,621 |
| May 4, 26 | Rhodes Jason P | sell | 3,136 |
| May 5, 26 | Rhodes Jason P | sell | 3,056 |
| May 6, 26 | Rhodes Jason P | sell | 21,926 |
Our DYN Coverage
We haven't published any research on DYN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DYN Report →